Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Figures & data

Figure 1. (a) Illustration of SARS-CoV RBD subunit S1. (b) Sequence alignment between SARS-CoV RBD219-N1 and SARS-CoV-2 spike protein. The RBM region is circled in green. An example of a neutralizing conformational epitope consisting S343–367, 373–390 and 411–428 (reported by Bian et al.) is circled in blue, indicating neutralizing epitopes do not have to be within RBM.⁷

Table 1. Neutralizing monoclonal antibodies reported in He et al, 2005¹¹ were categorized based on its ability to inhibit RBM binding to the ACE2.

Ability to block RBM binding to ACE2	Anti SARS-CoV RBD neutralizing mAb ID#	Number of antibodies
No	9F7, 10E7, 12B11, 18C2, 24H8,26E1, 29G2, 32H5, 20E7, 26A4, 27C1, 31H12, 30E10, 13B6	13
Partially	11E12, 18D9, 19B2	3
Yes	28D6, 30F9, 35B5, 24F4, 33G4, 38D4,	6
Not defined	26E1	1
	Total	23

Table 2. Binding study of anti-SARS-CoV RBD neutralizing mAb against the SARS-CoV-2 RBD

Anti SARS-CoV RBD neutralizing mAb ID#	Binding to RBM	Cross-reactivity of mAb to SARS-CoV-2 RBD
CR3022 ^Citation14	No	Bound potently (Tian et al., 2020)^Citation15
CR3014 ^Citation14,Citation17,Citation18	Yes	No binding (Tian et al., 2020)^Citation15
m396 ^Citation19,Citation20	Yes	Weakly or no binding (Tian et al., 2020; Wrapp et al., 2020)^15,16
80R ^Citation21	Yes	No binding (Wrapp et al., 2020)^Citation16
S230 ^Citation20,Citation22	Yes	No binding (Wrapp et al., 2020)^Citation16

Bian C, Zhang X, Cai X, Zhang L, Chen Z, Zha Y, Xu Y, Xu K, Lu W, Yan L, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology. 2009;383(1):39–46. doi:10.1016/j.virol.2008.09.029.

 PubMed Web of Science ®Google Scholar

Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, Shi ZL. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017;60(12):1399–402. doi:10.1007/s11427-017-9189-3.

 PubMed Web of Science ®Google Scholar

Ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi:10.1371/journal.pmed.0030237.

 PubMed Web of Science ®Google Scholar

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes Infect. 2020;9(1):382–85. doi:10.1080/22221751.2020.1729069.

 PubMed Web of Science ®Google Scholar

Ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004;363(9427):2139–41. doi:10.1016/S0140-6736(04)16506-9.

 PubMed Web of Science ®Google Scholar

van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(3):1635–44. doi:10.1128/JVI.79.3.1635-1644.2005.

 PubMed Web of Science ®Google Scholar

Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem. 2006;281(23):15829–36. doi:10.1074/jbc.M600697200.

 PubMed Web of Science ®Google Scholar

Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007;104(29):12123–28. doi:10.1073/pnas.0701000104.

 PubMed Web of Science ®Google Scholar

Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006;281(45):34610–16. doi:10.1074/jbc.M603275200.

 PubMed Web of Science ®Google Scholar

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;eabb2507. doi:10.1126/science.abb2507.

 Web of Science ®Google Scholar

Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008;82(7):3220–35. doi:10.1128/JVI.02377-07.

 PubMed Web of Science ®Google Scholar